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Investigation
Abstract

Background. Real-time collection of mental health and disease activity patient-reported outcomes (PROs) are
essential to assist clinicians in delivering optimal holistic health care. The aim of this pilot study was to validate
a digital support tool (DST) delivered via a tablet device in an outpatient setting to assess IBD activity and
psychological distress. Methods. 48 individuals (26 females; average age: 40.04) with IBD completed the
DST and a paper-based survey in a hospital IBD outpatient setting. PROs for disease activity and
psychological distress (Kessler K10) were compared to paper-based gold-standard measures of disease activity
(Partial Mayo Index or Harvey Bradshaw Index completed by the clinician) and psychological distress
(Depression Anxiety Stress Scale; completed by the patient). Patient feedback regarding usability and
acceptance of the DST was also collected. Results. DST patient-derived disease activity scores were
significantly correlated with clinician assessment of disease activity (p<0.01). Patient DST-derived
psychological well-being scores were also significantly correlated with the gold-standard measure of
psychological distress (p<0.05). Patients found the DST to be easy to use and identified a willingness to
follow through with the recommendations provided by the DST in relation to their psychological distress
scores. Conclusions. The pilot study demonstrates the value in collecting disease activity and psychological
distress PROs via a DST in an outpatient setting. Disease activity and psychological distress PROs were found
to correlate significantly with gold standard measures. The findings provide preliminary support for the value
of embedding digital technology into clinical care to promote patient engagement and optimal holistic
healthcare.
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Background. Real-time collection of mental health and disease activity patient-reported outcomes (PROs) are essential to assist
clinicians in delivering optimal holistic health care. The aim of this pilot study was to validate a digital support tool (DST)
delivered via a tablet device in an outpatient setting to assess IBD activity and psychological distress. Methods. 48 individuals (26
females; average age: 40.04) with IBD completed the DST and a paper-based survey in a hospital IBD outpatient setting. PROs
for disease activity and psychological distress (Kessler K10) were compared to paper-based gold-standard measures of disease
activity (Partial Mayo Index or Harvey Bradshaw Index completed by the clinician) and psychological distress (Depression
Anxiety Stress Scale; completed by the patient). Patient feedback regarding usability and acceptance of the DST was also
collected. Results. DST patient-derived disease activity scores were signiﬁcantly correlated with clinician assessment of disease
activity (p < 0 01). Patient DST-derived psychological well-being scores were also signiﬁcantly correlated with the gold-standard
measure of psychological distress (p < 0 05). Patients found the DST to be easy to use and identiﬁed a willingness to follow
through with the recommendations provided by the DST in relation to their psychological distress scores. Conclusions. The pilot
study demonstrates the value in collecting disease activity and psychological distress PROs via a DST in an outpatient setting.
Disease activity and psychological distress PROs were found to correlate signiﬁcantly with gold standard measures. The ﬁndings
provide preliminary support for the value of embedding digital technology into clinical care to promote patient engagement and
optimal holistic healthcare.

1. Introduction
Recently within the inﬂammatory bowel disease (IBD) literature, an emphasis has been on the development and validation of patient-reported outcomes (PROs) [1, 2]. PROs
provide researchers and clinicians with a validated collection
of assessment tools which can be utilised in research trials
and in general patient settings. The goal of such PROs is to
assess multiple aspects of health, including physical and
psychosocial outcomes derived from the patient [1]. To date,
several PROs have been investigated. For disease activity,
Jairath et al. [3] developed a 2-item-based PRO for ulcerative

colitis (UC), while Khanna et al. [4] proposed a 2- and 3item-based PRO for Crohn’s disease (CD). Other PROs
explored include disability [5], work productivity [6], anxiety, depression, and quality of life [2, 7].
In terms of patient settings, outpatient services provide
an ideal opportunity to collect PROs. As recommended by
several researchers [1, 2, 7], PROs collected in outpatient settings can provide clinicians with current and comprehensive
biopsychosocial assessments, in turn allowing for optimal
care, not only relating to physiological functioning but also
other essential areas such as psychological comorbidity. In
a recent systematic review, Mikocka-Walus and colleagues
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identiﬁed that up to 66% of IBD patients experience comorbid anxiety and/or depression [8]. Mental health issues have
also been identiﬁed to exacerbate IBD activity [9–11] and
increase the risk of disease ﬂare-ups [10, 12–14]. Given the
strong interrelationship between IBD and psychological
comorbidity, and the growing evidence base identifying the
impact of mental health on IBD, multiple IBD peak bodies
have recommended standards of IBD care that include the
review of and access to mental health services [15, 16].
The collection of disease activity and mental health PROs
in an outpatient setting could provide real-time information
to clinicians to facilitate a holistic optimal care approach.
Consequently, we sought to develop a digital support tool
(DST) application (or “app”) which could be delivered via a
tablet device in an outpatient setting to assess both disease
activity and mental health PROs.
The IBD patient assessment program (IBDPaP) is an
android-based DST app developed by the senior author
(SK) as a brief, easy to use, and ﬂexible platform to record
patient details. The DST collects a variety of biopsychosocial
markers of well-being, including disease activity and psychosocial functioning. IBD symptom activity questions were
derived from the Crohn’s Disease Activity Index (CDAI)
[17] and the Mayo Index [18]. The widely used and validated
Kessler 10-item psychological distress scale (K10) [19] was
used as the DST psychological distress PRO. IBDPaP also
assesses patient suicidality (“do you consider hurting yourself, others, or feel suicidal? Yes/no”), current engagement
with mental health services (“are you currently seeing a
mental health professional? Yes/no”), and willingness to seek
help (“do you have an appointment with a mental health
expert within the next 14 days or are you willing to contact
your local doctor (GP) if your mental health symptoms
worsen?”). After completing the IBDPaP, patients are provided with feedback about mental health status. Summary
reports can then be either emailed in PDF format to the
patient’s gastroenterologist or printed via a cloud device.
The aim of this pilot study was to validate a DST app
delivered via a tablet device to assess patient-reported outcomes (PROs) for IBD activity and psychological distress. It
was hypothesised that tablet-derived self-reported (1) disease
activity PRO for UC (SR-PRO2-UC) [3] would signiﬁcantly
correlate with clinician veriﬁed partial Mayo Score [18] and
PRO2 (PRO2-UC); (2) disease activity PROs for CD
(SR-PRO2-CD and SR-PRO3-CD) [4] would signiﬁcantly
correlate with clinician-veriﬁed Harvey Bradshaw Index
[20] and 2- and 3-item-based PRO for CD (PRO2-CD and
PRO3-CD); (3) psychological distress (K10) would correlate
signiﬁcantly with a validated paper-based distress score
(Depression Anxiety Stress Scale; DASS); and (4) patient
feedback regarding mental health recommendations and
app-based usability and usefulness would be positive.

2. Materials and Methods
2.1. Patients. Eighty-one participants (47 female, mean age
38.28, SD = 14 76; 48 with Crohn’s disease) from an IBD outpatient service completed a DST. From the initial 81 participants, 48 (26 female, mean age 40.04. SD = 15 38; 25
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with Crohn’s disease; average number of years diagnosed
9.62) also completed a paper-based survey. One patient
had a diagnosis of indeterminate colitis and was excluded
from the analysis.
2.2. Measures
2.2.1. Paper-Based Measures
(1) Modiﬁed Harvey-Bradshaw Index (MHBI). The HarveyBradshaw Index (HBI) [20] is an eﬃcient way to assess disease activity in CD patients. Respondents score 5 items
based on how they felt the previous day. Items include general well-being, abdominal pain, number of liquid or soft
stools per day, abdominal mass, and additional manifestations. In the present study, however, the modiﬁed HBI
(MHBI) was used due to its improved simplicity and functionality. The MHBI is identical to the HBI, except that the
question on abdominal mass is omitted, removing the need
for physical examination of the patient. The MHBI has also
been utilised in other cross-sectional studies with CD
patients [21, 22]. Higher scores on the MHBI indicate
greater disease severity, with scores equal to or below 5
indicating clinical remission.
(2) Patient-Reported Outcome for Crohn’s Disease (PRO2-CD
and PRO3-CD). The 2- and 3-item PRO for CD (PRO2-CD
and PRO3-CD, respectively) was based on items taken from
the MHBI as described by Khanna et al. [4]: loose bowel
movements [number of liquid or very soft stools] (×2),
abdominal pain [0 = none, 1 = mild, 2 = moderate, 3 =
severe] (×5), and for the third item, general well-being
[0 = very well, 1 = slightly below par, 2 = poor, 3 = very poor,
4 = terrible] (×7). Higher scores indicated greater disease
activity. For the 2-item PRO CD, remission was deﬁned as
a mean daily stool frequency ≤ 1 5 and abdominal pain
score ≤ 1. For the 3-item PRO CD, the additional criterion
for remission was a general well-being score of ≤1.
(3) Partial Mayo Index (PMI). The Mayo Index [18] is a popular measure of ulcerative colitis disease activity. It includes
stool frequency, rectal bleeding, mucosal appearance, and
physician rating of disease activity. However, research suggests that the inclusion of endoscopic components, such as
mucosal appearance, does not signiﬁcantly contribute to the
predictive value of the index [23]. Thus, in the current study,
the noninvasive Partial Mayo Index (PMI) was used. All
items are scored from 0 to 3, with the total being out of 9;
scores equal to or below 1 indicate remission.
(4) Patient-Reported Outcome for Ulcerative Colitis (PRO2UC). The PRO2-UC was based on two items from the PMI
as described by Jairath et al. [3]: stool frequency (normal
[+0], 1-2 stools/day more than normal [+1], 3-4 stools/day
more than normal [+2], >4/day more than normal [+3]) and
rectal bleeding (none [+0], visible blood with stool less than
half the time [+1], visible blood with stool half of the time or
more [+2], passing blood alone [+3]). Remission was deﬁned
as rectal bleeding = 0 and absolute stool frequency ≤ 2.
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IBD Activity

Condition

IBD Activity

General well-being over the last week
Very well

Number of years diagnosed with IBD

Slightly below par
Poor

In the past 3 months my IBD has been

Very poor
Terrible

Over the past week, how many bowel
movements have you had per day
Over the past week, how many of your
bowel movements have been loose/
watery stools per day

Over the past week, my rectal bleeding has
been
None
Streaks of blood
Obvious blood
Mostly blood

Next
Over the past week have you taken any
antidiarrheal medication
Yes
No

Figure 1: Example of IBD symptom activity questions presented in the IBDPaP and used in the calculation of disease activity PROs.

(5) Short Form of the Depression Anxiety Stress Scales
(DASS21). The DASS21 is a validated measure of psychological distress [24, 25]. The scale consists of 21 statements, which assess individual distress in the domains of
depression, anxiety, and stress. Respondents rate how
much each statement applied to them over the past week,
using a 4-point Likert scale, ranging from zero (did not
apply to me at all) to three (applied to me very much or
most of the time). A total distress scale score (0–126) is
derived by summing the items and multiplying by 2
[26]. Higher scores indicate greater distress in the corresponding domains.
2.2.2. DST-Based Measures
(1) Disease Activity—Patient-Reported Outcomes (PROs).
Similar to the paper-based UC PROs, the items for the
SR-PRO2-UC were primarily based on the PMI. However,
slight modiﬁcations based on gastroenterologist feedback
were made to ensure patients were able to answer the questions most accurately and objectively. Based on these modiﬁcations, the 2-item disease activity score [3] was created
(SR-PRO2-UC; how many bowel movements do you have
per day? (0-2 stools/day [+0], 3 stools/day [+1], 4 stools/day
more than normal [+2], >5 or more/day more than normal
[+3]) and rectal bleeding (rectal bleeding over the last week:
none [0], streaks of blood [+1], obvious blood [+2], mostly
blood [+3]), with higher scores indicating greater disease
activity. Remission was deﬁned as rectal bleeding = 0 and
absolute stool frequency ≤ 2.
For CD patients, disease activity PRO scores [4] used HBI
but modiﬁed items based on gastroenterologist feedback. The
2- and 3-item disease activity PRO scores (SR-PRO2-CD

and SR-PRO3-CD) assessed bowel movements (how many
of your bowel movements are loose/watery stools per day?
[number of liquid or very soft stools] (×2)), abdominal
pain/cramping (have you experienced abdominal pain or
cramping over the last week? [0 = none, 1 = mild, 2 =
moderate, 3 = severe] (×5)), and for the third item, general
well-being over the last week [0 = very well, 1 = slightly
below par, 2 = poor, 3 = very poor, 4 = terrible] (×2), with
higher scores indicating greater disease activity. For the
2-item PRO CD, remission was deﬁned as a mean daily
stool frequency ≤ 1 5 and abdominal pain score ≤ 1. For
the 3-item PRO CD, the additional criterion for remission
was a general well-being score of ≤1. See Figure 1 for
example IBD symptom activity questions presented in
the IBDPaP.
(2) Kessler Psychological Distress Scale (K10)–Patient-Reported
Outcome (PRO). The Kessler Psychological Distress Scale
(K10) [27] is a 10-item questionnaire, commonly used as an
indicator of mental health status. Respondents answer a series
of questions regarding their mental health experiences over the
past 30 days, using a 5-point Likert scale from one (none of the
time) to ﬁve (all of the time) (see Figure 2 for IBDPaP K10
screenshot). K10 scores between 10-15, 16-30, and 31-50 were
identiﬁed with minimal, moderate, or severe psychological
distress, respectively.
(3) Suicidality. A single question, “do you consider hurting
yourself, others, or feel suicidal,” was also included into the
tablet-based survey as a means to alert the clinician to any
patients at heightened risk of self-harm or suicide. Patients
who answered “yes” to this question would subsequently
receive a feedback page which advised them to seek support
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Mental Health Review

Mental Health Review

During the last 30 days, about often did
you feel tired out for not good reason?

During the last 30 days, about often did
you feel so restless you could not sit still?

During the last 30 days, about often did
you feel nervous?

During the last 30 days, about often did
you feel depressed?

During the last 30 days, about often did
you feel so nervous that nothing could
calm you down

During the last 30 days, about often did
you feel that everything was an effort?

During the last 30 days, about often did
you feel hopeless?

During the last 30 days, about often did
you feel so sad that nothing could cheer
you up?

During the last 30 days, about often did
you feel restless or fidgety?

During the last 30 days, about often did
you feel worthless?

Previous

Next

Previous

Next

Figure 2: IBDPaP K10 screenshot.

Mental Health Status

Mental Health Status

Individuals tend to report minimal levels of
psychological distress
For further information and strategies to
manage psychological distress related to:

Mental Health Status

Individuals tend to report some symptoms
which may be associated with psychological
distress. These symptoms may be causing
some distress in your life.
We recommend you meet with your mental
health professional if symptoms worsen. For
further information and strategies to manage
psychological distress please go to

Individuals tend to report strong and frequent
symptoms which may be associated with
psychological distress
Unless you are doing so already, we
recommend you contact your mental health
professional or doctor as soon as possible to
arrange a mental health review.

Depression Anxiety

http://www.beyondblue.org.au/

If you have any questions or concerns please
talk to your mental health professional

Depression Anxiety

http://www.beyondblue.org.au/

Next

If you have any questions or concerns please
talk to your mental health professional

Are you considering
harming yourself
or thinking about
suicide?
Please talk about
these thoughts/
feelings with
yourhealth
professional or
doctor.

Saving
Lives
Crisis Support Suicide Prevention

13 11 14
(24/7)

Crisis Chat
(Available every night)

Lifeline.org.au

Next
Please review these results with your mental
health professional.

Next

Figure 3: Mental health feedback responses, delivered dependent on the reported levels of psychological distress from low (left) and moderate
(middle) to severe (right).

and to talk with their doctor (see Figure 3). Additionally,
patients’ IBDPaP reports were emailed to their gastroenterologists, which ensured that appropriate referrals to mental
health professionals could also be provided for patients
deemed to be at increased risk.

(4) Automatic Feedback and Recommendations Tablet-Based
Psychological Distress Screening. Based upon responses from
the K10 and suicidality question, patients were presented
with automatically generated feedback and recommendations (see Figure 3). If respondents identiﬁed any suicidality,
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they were provided with the same feedback provided to the
severe K10 distress category.
(5) DST Experience. Eight questions assessed patient opinions
and experiences in relation to using the DST (e.g., “how easy
was it to use this tablet-based program?”) and receiving the
automated feedback (e.g., “how helpful was this advice?”
and “how likely are you to follow up on the advice that was
provided?”), as well as the perceived beneﬁt of integrating
the DST into their ongoing care (e.g., “do you feel the information collected in this tablet-based program will help you
and your gastroenterologist better manage your IBD in a collaborative way?” and “do you feel more motivated to manage
your IBD after completing this tablet-based program?”).
Questions were assessed on a 10-point Likert scale, e.g., 0 =
“
not at all” to 10 = “ very much so.”
2.3. Procedure. Patients were approached at the IBD outpatient service. Consenting participants completed the IBDPaP
DST on a Samsung 8” tablet and were then provided with a
paper-based questionnaire. Patients could choose to complete the questionnaire while waiting for their appointment
or complete at home within 24 hours and mail back using
the prestamped and addressed envelopes. During the outpatient appointment, the clinician completed the patient’s disease activity measures (i.e., PMI or HBI) in the paper-based
questionnaire. Ethical approval was attained from the local
university and hospital ethics committees prior to commencing the study.
2.4. Data Analyses. Analyses were conducted using IBM SPSS
version 21. To allow for combined analysis of IBD disease
activity across both CD and UC patients, the MHBI and
PMI scores were ﬁrst converted into Z-scores. Chi-square
and t-tests were used to examine potential diﬀerences in
demographic and psychometric variables between those
who did and did not complete the paper-based questionnaire.
Correlation analyses were performed to determine whether
the tablet-derived disease activity PROs were associated with
clinician-veriﬁed indices and paper-based PROs. Additionally, the correlation analysis examined whether the tabletbased psychological distress (K10) PRO was associated with
the paper-based DASS21. Given that the assumption of normality was violated for several of the variables, Spearman’s
rho was utilised for all correlational analyses. Descriptive statistics on patients’ experiences with the tablet-based survey
were also explored.

3. Results
There were no signiﬁcant diﬀerences in age, gender, or
disease type and severity between those who did and did
not complete the paper-based surveys. Similarly, there were
no signiﬁcant diﬀerences in psychological distress between
these two groups. Of the 47 CD and UC patients who completed both the tablet- and paper-based surveys, the K10
scores identiﬁed 15 responders (31.9%) to be experiencing
minimal psychological distress, while 27 (57.4%) had moderate psychological distress and 5 (10.6%) indicated severe
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psychological distress. Five participants (10.4%) identiﬁed
positively to suicidal ideation and either not having an
appointment with a mental health expert within the next 14
days or willing to contact their local doctor (GP) if their mental health symptoms worsen. All 5 participants were subsequently assessed during the gastroenterology appointment
and provided an appropriate referral.

4. Relationships between Tablet- and
Paper-Based Measures of Disease Activity
and Psychological Distress
Prior to assessing relationships involving the disease activity
PROs, diﬀerences in item format between gastroenterologist
and patient self-completed disease activity items were evaluated. A series of t-tests indicated that there were no signiﬁcant diﬀerences, suggesting similar responses by both
gastroenterologists and patients despite the slight wording
diﬀerences in items and response format.
There was consistency across each measure of disease
activity for both CD and UC, with all related disease activity
measures showing signiﬁcant interrelations (see Table 1).
Speciﬁcally, the tablet-derived PROs for CD demonstrated
strong signiﬁcant correlations with clinician-veriﬁed MHBI
scores and paper-based CD PROs. Likewise, the tabletderived PROs for UC were found to have a strong signiﬁcant
correlation with the clinician-veriﬁed Partial Mayo Index and
the paper-based UC PRO although these correlations were
stronger when using clinician-derived PRO scores (e.g.
PRO2-CD) versus patient-derived PRO scores (e.g. PRO2CDSR). Patient scores on the tablet-derived K10 showed a
strong positive association with scores on the paper-based
DASS21. This demonstrates that psychological distress scores
were also consistent across tablet- and paper-based measures.
4.1. Accuracy of Remission Rates across Tablet- and PaperBased Disease Activity Measures. Table 2 shows there was a
strong overlap between the percentage of patients in remission across clinician-reported measures of disease activity
and PROs for both CD and UC. While the PROs typically
identiﬁed fewer patients as being in remission than the
clinician-reported measures, the percentage overlap was similar between both the paper- and tablet-derived PROs.
4.2. Patient Perceptions of DST Experience. Examination of
descriptive statistics on patients’ experiences with the tabletbased survey (see Figure 4) suggested that most patients found
the tablet easy to use (M = 7 51, SD = 1 02) and found it helpful (M = 6 54, SD = 1 89). Similarly, several patients felt motivated to manage their IBD after completing the survey
(M = 5 46, SD = 2 13) and reported the information collected
to be helpful to both themselves and their gastroenterologist
in the management of their IBD (M = 5 98, SD = 2 07).
As shown in Figure 5, the results indicated that the
instant feedback and advice were often perceived to be helpful (M = 5 44, SD = 1 99) and consistent with patients’ sense
of mental health (M = 5 51, SD = 2 28). While fewer patients
reported that they would highly likely follow the advice given
(M = 4 71, SD = 2 05), patients did not typically report high
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Table 1: Spearman’s rho correlations and descriptive statistics of disease activity and psychological variables.
1

2

3

4

5

2. MHBI (paper)

—
1.00∗∗∗

3. PRO2-CD

0.95∗∗∗ 0.95∗∗∗

4. PRO3-CD

0.88∗∗∗ 0.88∗∗∗ 0.88∗∗∗

5. PRO2-CDSR (tablet)

0.81∗∗∗ 0.81∗∗∗ 0.82∗∗∗ 0.78∗∗∗

1. Standardized disease activity scores

∗∗∗

6. PRO3-CDSR (tablet)

0.79

7. Partial Mayo (paper)

0.99∗∗∗

6

7

8

9

10

Mean (SD)
0.04 (1.00)

—

0.79

3.52 (3.29)

∗∗∗

—

—

∗∗∗

7.20 (6.17)
13.64
(12.20)

—

∗∗∗

0.78

0.82

—

—

—
0.96

8.92 (10.92)

∗∗∗

—

15.92
(17.26)

—
—

—

1.32 (2.08)

8. PRO2-UC

∗∗∗

0.97

—

—

—

—

—

0.99

9. PRO2-UCSR (tablet)

0.56∗∗

—

—

—

—

—

0.55∗∗ 0.58∗∗

10. K10 (tablet)

0.45∗∗

0.57∗

0.57∗∗

0.67∗∗

11. DASS21 (paper)

0.30∗

0.42∗

0.35

0.40

0.60∗∗ 0.68∗∗∗
0.40∗

0.38

∗∗∗

—

0.91 (1.11)
—

1.50 (1.54)

0.17

0.22

0.43∗

0.02

0.06

0.38 0.74∗∗∗

—

20.17 (8.21)
15.68
(13.79)

Note. ∗ p < 0 05, ∗∗ p < 0 01, ∗∗∗ p < 0 001.

Table 2: Percentage of patients in remission across both CD and UC measures and PROs.
Sample
(n)
MHBI
PRO2-CD
PRO3-CD
PRO2CDSR
PRO3CDSR

25
25
25
25
25

Crohn’s disease
Patients in
remission (%)
80.0%
60.0%
52.0%
48.0%
48.0%

Correct overlap with
MHBI (%)
—
80.0%
72.0%
68.0%
68.0%

Sample
(n)

Ulcerative colitis
Patients in
remission (%)

Correct overlap with
PMI (%)

22
22
22

72.7%
90.9%
59.1%

—
81.8%
77.3%

PMI
PRO2-UC
PRO2UCSR

Do you feel more motivated to manage your IBD
after completing this tablet-based program?
Do you feel that the information collected in this
tablet-based program will help you and your
gastroenterologist better manage your IBD in a…
How helpful was it to use this tablet based
program?
How easy was it to use this tablet-based program?
1

2

3

4

5

6

7

8

Figure 4: Patient perceptions on use of tablet-based program.

levels of distress after receiving the feedback (M = 2 43,
SD = 1 85).

5. Discussion
Optimal management of a patient’s well-being requires the
collection of information in a timely and accurate way.
DSTs are increasingly being identiﬁed as an important
technology which can be embedded within traditional
healthcare practice to help facilitate the monitoring and

management of patient well-being. The current pilot study
aimed to validate the IBDPaP, a DST designed to be utilised
in IBD outpatient settings to (a) collect information regarding disease activity and mental health and (b) provide recommendations based upon participant mental health scores.
The results provided support for the ﬁrst hypothesis that
the IBDPaP DST patient-reported disease activity PROs for
UC and CD signiﬁcantly correlated with the clinicianderived disease activity PROs. Further, exploration of disease
activity PROs dichotomised into either active or nonactive
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Are the results provided consistent with your
sense of current mental health status?
Did you experience any distress after receiving
feedback about your results?
How likely are you to follow up on the advice
that was provided?

How helpful was this advice?
1

2

3

4

5

6

7

8

Figure 5: Patient perceptions on mental health feedback.

cases indicated that clinician-derived PROs could correctly
identify remission status (compared against cliniciancompleted HMBI or PMI) in 72-80% of CD patients and
81.8% of UC patients. Likewise, consistency for patientderived PROs was not much lower, with remission status
identiﬁed correctly in 68% of CD patients and 77.3% of UC
patients. Interestingly, this demonstrates that while
clinician-derived PROs were understandably more accurate
in classifying active or nonactive cases, the patient-reported
PROs were correct in a high proportion of cases also. However, given that around 20% of cases are misclassiﬁed when
using clinician-derived PROs, further work on developing
these PROs is needed. Despite the identiﬁed limitations, the
results provide preliminary support for the use of a DST to
collect disease activity PROs. With further research, DSTs
could become highly valuable and eﬃcacious in informing
clinicians about their patients’ current IBD symptoms, severity, and perceived illness status. The ﬁndings also provide
further evidence for the value of assessing PROs in outpatient
settings [1, 2, 7].
Supporting the study’s third and fourth hypotheses were
the ﬁndings that the IBDPaP DST patient-reported psychological distress score was signiﬁcantly correlated with the
paper-based distress score (DASS21) and that patients perceived the IBDPaP DST as easy to use and helpful, whilst
motivating them to better manage their symptoms. While
patients identiﬁed that the feedback from the DST based
upon their mental health scores was helpful, they reported
being less likely to follow up on the advice provided. Importantly, of the participants who completed the IBDPaP DST, 5
participants (10.4%) identiﬁed positively to suicidal ideation
and were subsequently assessed and referred appropriately.
The ﬁndings suggest that while IBDPaP DST was accurate
and helpful in collecting patient psychological distress status,
its recommendations provided were not necessarily going to
be followed up by patients. While these ﬁndings may reﬂect
the reluctance of patients with IBD to seek mental health support [28, 29], it was clear that the collection of this data was
helpful in identifying suicidality and informing clinicians
about their patients’ psychological well-being. The ﬁndings
are also consistent with past research and recommended care
standards identifying the importance of assessing mental
health issues in IBD cohorts [8, 15, 16].

As identiﬁed above, an important ﬁnding from this pilot
study was that patients respond positively to app-based
usability and usefulness. Thus, while further research is
important to determine the eﬃcacy of the IBDPaP in improving features of patient care, these ﬁndings provide evidence
that the integration of DST apps such as the IBDPaP can be
well-accepted by patients and therefore hold great potential
for improving patient and clinical management of IBD in
the future.
However, the current study is not without limitations.
While disease activity was assessed using validated measures,
it did not utilise the full-scale and unmodiﬁed versions which
include objective measures such as endoscopic information
and biomarkers such as faecal calprotectin. Future research
would beneﬁt from utilising full-scale measures of disease
activity along with objective measures and biomarkers. While
it is essential that disease activity PROs are assessed, it is also
worth noting that at this time, research validating such PROs
is limited. Further, our study identiﬁed that the overlap
between these PROs and standardised measures was low
(e.g., 68% overlap for self-report CD PROs and MHBI).
Clearly, further research is needed to develop well-validated
and accurate disease activity PROs. In relation to patient
completed PROs (PRO2CDSR, PRO3CDSR, and PRO2
UCSR), due to the DST not diﬀerentiating between disease
type, it instead asked the same disease-related questions.
Consequently, to reduce patient question fatigue and
improve patient understanding, a reduced number and combination of HBI and PMI items were used. Further research is
needed to validate format and type of questions used to assess
disease activity PROs as completed by patients using such
tools as the DST. The study also did not assess the perceived
utility of the IBDPaP DST as perceived by clinicians. Anecdotal feedback from clinicians was that the IBDPaP DST
was easy to implement in the service, useful in helping to
inform patient disease management plans, and provided a
way to identify and explore patient perceptions relating to
their physical and mental health. Future research should formally assess the perceptions of patients and clinicians in relation to the value of the IBDPaP DST in IBD outpatient
settings. Future research could also explore the potential utility of adapting the DST to enable patients to provide disease
activity (including faecal calprotectin values) and mental
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health symptoms on a regular basis at home along with data
collection during an outpatient appointment. Finally, while
the pilot study provides promising results, future research
should be undertaken using a larger sample size stratiﬁed
by disease class, gender, and age to evaluate the temporal reliability of the IBDPaP DST.

Gastroenterology Research and Practice

[4]

[5]

6. Conclusion
In the age of “apps” and patient empowerment, integrating
DSTs to assess PROs prior to clinic visits will assist both
patients and clinicians in focusing on what is important.
Despite the small sample size, the study demonstrated
strong correlations between IBDPaP DST patient-derived
disease activity PROs and clinician-derived disease activity
scores, as well as between patient-derived mental health
PROs and a gold standard mental health measure. Further,
the IBDPaP DST was able to alert clinicians to suicidal ideation in patients. An important ﬁnding from this pilot study
was that patients found the IBDPaP DST to be beneﬁcial,
easy to use, and it was perceived that the app would assist
patients and their gastroenterologists to better manage IBD
in a collaborative way. Our study suggests that the IBDPaP
is well received by patients and therefore presents a feasible
approach for the facilitation of patient engagement and optimal holistic healthcare.
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